Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Operating Expenses: 2023-2025

Historic Operating Expenses for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to $36.4 million.

  • Tonix Pharmaceuticals Holding's Operating Expenses rose 97.85% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.2 million, marking a year-over-year decrease of 27.90%. This contributed to the annual value of $146.8 million for FY2024, which is 16.37% up from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Operating Expenses is $36.4 million, which was up 20.01% from $30.3 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Operating Expenses' 5-year high stood at $79.5 million during Q2 2024, with a 5-year trough of $18.4 million in Q3 2024.
  • Moreover, its 3-year median value for Operating Expenses was $30.3 million (2025), whereas its average is $32.8 million.
  • The largest annual percentage gain for Tonix Pharmaceuticals Holding's Operating Expenses in the last 5 years was 97.85% (2025), contrasted with its biggest fall of 61.91% (2025).
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Operating Expenses stood at $31.1 million in 2023, then declined by 19.44% to $25.1 million in 2024, then soared by 97.85% to $36.4 million in 2025.
  • Its last three reported values are $36.4 million in Q3 2025, $30.3 million for Q2 2025, and $18.5 million during Q1 2025.